Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Mother and Infant Visit Adherence and Treatment Engagement Study (MOTIVATE!)

22 april 2021 bijgewerkt door: University of Colorado, Denver

Maximizing Adherence and Retention for Women and Infants in the Context of Option B+

This is a 2x2 factorial cluster randomized trial of two interventions to improve retention and adherence for women and infants on Option B+. The overall goal is to determine which intervention (or combination of interventions) maximizes antiretroviral therapy (ART) adherence and retention in care in the context of Option B+ and thus improves maternal and infant health outcomes.The proposed study will be conducted in rural Nyanza Province, Kenya at 20 low-resource primary health care facilities and associated communities supported by Family AIDS Care and Education Services (FACES), a President's Emergency Plan for AIDS Relief (PEPFAR)-funded HIV prevention care, and treatment program, ((AIDS) acquired immune deficiency syndrome, (HIV) human immunodeficiency virus) . The investigators will assess both process and outcome indicators using a 2x2 factorial design, in which equal numbers of clusters will be randomized to one of the interventions (community-based mentor mothers or theory-based mobile text messages), both interventions, or standard of care. The interventions will be added to fully integrated high quality HIV and antenatal, maternal, neonatal, and child health (ANC/MNCH) services already offered at these sites.

Studie Overzicht

Gedetailleerde beschrijving

In order to eliminate new pediatric HIV infections, save maternal lives, and simplify antiretroviral therapy (ART) implementation in settings with generalized HIV epidemics, current World Health Organization (WHO) guidance recommends lifelong triple ART for all pregnant and breastfeeding women (Option B+). However, despite the promise of Option B+ to remove logistical barriers and to promote maternal health through life-long ART, this strategy brings challenges. Key amongst these challenges are adherence to ART and continuous retention in HIV care, especially for women who do not require ART for their own health. Barriers to adherence and retention in care for prevention of mother-to-child transmission (PMTCT) have been identified at the individual, interpersonal, community, and health facility levels; yet specific barriers in the context of Option B+ are not well understood. The investigators' study will be conducted at 20 health facilities and associated communities in Nyanza Province, Kenya where Mother to Child Transmission (MTCT) rates prior to Option B+ roll-out remained near 10%, despite the wide availability of PMTCT services. As Option B+ is scaled up in Kenya, it is essential to identify effective methods to ensure long-term adherence and retention in care for mother-baby pairs, throughout pregnancy, breastfeeding, and beyond. Building on the investigating team's prior research experience in this setting, the investigators propose to gain understanding of and address potential barriers at the individual, community, and health facility levels through formative research with HIV-positive pregnant and postpartum women, their male partners, and health care providers. This information will be used to refine two proposed interventions that are highly likely to maximize ART adherence and retention in care among HIV-infected pregnant women and HIV-exposed infants. These interventions will be rigorously tested in rural Kenya, using a cluster randomized 2x2 factorial design. The evidence-based interventions to be tested will include 1) community Mentor Mothers (cMM) who will provide support for ART adherence and retention in care for HIV-positive women in the community and 2) individually tailored, theory based mobile phone text messages to help retain women and infants in HIV care. The investigators' overall goal is to determine which intervention (or combination of interventions) maximizes ART adherence and retention in care in the context of Option B+ and thus improves maternal and infant health outcomes. The investigators' primary outcomes will include ART adherence at 12 months postpartum and retention in care, measured by a documented HIV care visit within 90 days prior to 12 months postpartum. Secondary outcomes will include MTCT at 6 weeks, 12 months and 18 months; as well as maternal viral loads and CD4 counts. Results from this study will inform the scale-up of Option B+ in Kenya by identifying effective interventions and combinations of interventions that can reduce barriers and increase facilitators of optimal ART adherence and retention in care with the aims of reaching the elimination of mother to child transmission of HIV and significantly improving maternal health.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

1338

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Nairobi, Kenia
        • Kenya Medical Research Institute

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria:

  • Age 18 years or older,
  • HIV-infected pregnant women and their HIV-exposed infants pairs,
  • attends the antenatal care (ANC) clinic at one of the study sites.

Exclusion Criteria:

  • Less than 18 years of age,
  • HIV-infected women not currently pregnant,
  • not HIV-infected at the time of the first ANC visit.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Faculteitstoewijzing
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Ander: cMM and Text Messaging
Participants randomized to this arm will receive both the community mentor mother and mobile phone text messaging intervention. The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits. The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
Home visits from community mentor mothers
Text messages received on mobile phone
Ander: cMM Only
Participants randomized to this arm will receive the community mentor mother intervention only.The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits.
Home visits from community mentor mothers
Ander: Text Messaging Only
Participants randomized to this arm will receive the mobile phone text messaging intervention only. The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
Text messages received on mobile phone
Geen tussenkomst: Neither cMM nor Text Messaging
Participants randomized to this arm will receive standard of care with no interventions.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Self-reported adherence on antiretroviral therapy
Tijdsspanne: 12 months post-partum
Self-report
12 months post-partum
Adherence on antiretroviral therapy
Tijdsspanne: 12 months post-partum
Viral load<100 copies/ml based on medical records
12 months post-partum
Adherence on antiretroviral therapy (infant)
Tijdsspanne: 12 months post-partum
Use of ARVs for the infant
12 months post-partum
Retention in care
Tijdsspanne: 12 months post-partum
Proportion of women who have an HIV care visit within 90 days at 12 months after the birth
12 months post-partum
Adherence on antiretroviral therapy (dried blood spots)
Tijdsspanne: 12 months post-partum
Viral load<100 copies/ml based on dried blood spots
12 months post-partum

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Maternal CD4 count change
Tijdsspanne: 6 months after baseline
Change in CD4 count baseline to 6 months after baseline
6 months after baseline
Maternal viral load count change
Tijdsspanne: 6 months after baseline
Change in viral load from baseline to 6 months after baseline
6 months after baseline
Infant retention in care (feeding method)
Tijdsspanne: 12 and 18 months
Infant feeding method
12 and 18 months
Infant retention in care
Tijdsspanne: 12 and 18 months
Retention in care through 12 and 18 months
12 and 18 months
Infant retention in care (survival status)
Tijdsspanne: 12 and 18 months
Survival status of infant
12 and 18 months
Uptake of intervention services (Number/types of text messages sent)
Tijdsspanne: 3 years
Number/types of text messages sent
3 years
Uptake of intervention services (receipt of text messages)
Tijdsspanne: 3 years
Receipt of text messages
3 years
Uptake of intervention services (home visits)
Tijdsspanne: 3 years
Number of home visits received
3 years
Uptake of intervention services (support groups attended)
Tijdsspanne: 3 years
Number of support groups attended.
3 years
Mother-to-Child-Transmission
Tijdsspanne: 6 weeks, 9 months and 18 months
Result of infant HIV test at 6 wks, 9,18 months
6 weeks, 9 months and 18 months
Infant testing
Tijdsspanne: 6 weeks, 9 months and 18 months
Uptake and date of infant testing
6 weeks, 9 months and 18 months
Infant enrollment in care
Tijdsspanne: 6 weeks
Infant enrollment in HIV care
6 weeks
Male partner involvement
Tijdsspanne: 12 months post-partum
Composite variable including Y/N response to indicate if male partner attended a health visit with his female partner, encouraged facility delivery, reminded to take HIV medication, reminded to go for HIV care, provided transport money to go to the clinic/dispensary, reminded to give the infant prophylaxis, helped giving the infant prophylaxis medication, collected medication for the woman or infant, encouraged specific infant feeding, and encouraged pediatric HIV testing. These are assessed in the follow-up questionnaires completed at 12 months post-partum.
12 months post-partum

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 mei 2014

Primaire voltooiing (Werkelijk)

1 april 2019

Studie voltooiing (Werkelijk)

1 maart 2021

Studieregistratiedata

Eerst ingediend

11 maart 2015

Eerst ingediend dat voldeed aan de QC-criteria

2 juli 2015

Eerst geplaatst (Schatting)

7 juli 2015

Updates van studierecords

Laatste update geplaatst (Werkelijk)

26 april 2021

Laatste update ingediend die voldeed aan QC-criteria

22 april 2021

Laatst geverifieerd

1 april 2021

Meer informatie

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Klinische onderzoeken op Humaan Immunodeficiëntie Virus

Klinische onderzoeken op cMM

3
Abonneren